New drug combo shows promise for rare autoimmune disease

NCT ID NCT04520451

Completed Disease control Sponsor: Principia Biopharma, a Sanofi Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called rilzabrutinib combined with steroids in 27 adults with active IgG4-related disease, a rare condition causing inflammation and organ damage. The goal was to see if the combination could prevent disease flares better than steroids alone. Participants took the drug daily and were monitored for safety and disease activity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IGG4-RELATED DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Immunoglobulin G4-Related Disease immunoglobulin G4-related sclerosing disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNOGLOBULIN G4 RELATED DISEASE

Contacts and locations

Locations

Investigational Site Number 12403

Vancouver, V6K 2V8, Canada
Investigational Site Number 25013

Marseille, France
Investigational Site Number 38016

Milan, Italy
Investigational Site Number 72415

Barcelona, Spain
Investigational Site Number 84016

Boston, Massachusetts, 02114, United States
Investigational Site Number 84018

Detroit, Michigan, 48202, United States
Investigational Site Number 84019

Stanford, California, 94305, United States
Investigational Site Number 84030

New York, New York, 10021, United States
Investigational Site Number 84036

Portland, Oregon, 97239, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.